USFDA accepts Panacea Biotech's ANDA for breast cancer drug
Panacea Biotech confirms that the USFDA has accepted its abbreviated new drug application to evaluate its dossier for marketing paclitaxel protein-bound particles for injectable suspension in the US30-11-2017